hepatology

Events

Partner Content

Welcome to the 2nd Chronic HBV Drug Development Summit

Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis B.

News

Madrigal sings praises of NASH drug resmetirom

After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have failed, and finally bring a drug to market to treat the liver disease non-alc

News

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences.

News

Ipsen places €480m bet on Genfit's liver drug elafibranor

Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and

News

Digital health firm ChronWell raises $6m for liver disease t...

US remote healthcare specialist ChronWell has raised $6 million from investors that will be used to accelerate the rollout of its patient management programmes for people with liver and gas

News

Intercept's travails continue as it pulls NASH drug filing i...

Already scrambling to refile its obeticholic acid (OCA) drug for non-alcoholic steatohepatitis (NASH) after the FDA rejected it last year, Intercept Pharma was hoping for more luck in Europ

Welcome to the 2nd Chronic HBV Drug Development Summit

Madrigal sings praises of NASH drug resmetirom

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

Ipsen places €480m bet on Genfit's liver drug elafibranor

Digital health firm ChronWell raises $6m for liver disease t...

Intercept's travails continue as it pulls NASH drug filing i...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

hepatology

Editor's Picks